Toddlers who undergo total body irradiation in preparation for bone marrow transplantation are at higher risk for a decline in IQ and may be candidates for stepped up interventions to preserve intellectual functioning, St. Jude Children's Research Hospital investigators reported. The findings appear in the current issue of the Journal of Clinical Oncology.

The results clarify the risk of intellectual decline faced by children, teenagers and young adults following bone marrow transplantation. The procedure is used for treatment of cancer and other diseases. It involves replacing the patient's own blood-producing stem cells with those from a healthy donor.

Researchers tracked IQ scores of 170 St. Jude patients before and for five years after transplantation, making this the most comprehensive effort yet to determine how the procedure affects intelligence. The patients ranged in age from 4 months to 23 years when their transplants occurred. The procedure had little lasting impact on the IQ scores of most patients.

"For the great majority of patients, these findings provide reassurance that transplantation will not have a significant negative impact on cognitive development," said corresponding author Sean Phipps, Ph.D., chair of the St. Jude Department of Psychology. "We have also identified a high-risk group of younger patients who may benefit from more intensive interventions, including developmental stimulation and other rehabilitative therapies designed to prevent a decline in intellectual functioning and aid in recovery."

The high-risk group includes patients whose transplants occurred when they were aged 3 years or younger and involved total body irradiation (TBI). TBI is used to prepare patients for transplantation by killing remaining cancer cells and protecting the transplanted cells from their immune systems. TBI is associated with a range of short-term and long-term side effects. At St. Jude, therapeutic advances have significantly reduced the use of TBI in bone marrow transplantations.

Previous studies of bone marrow transplantation survivors reported conflicting results about the long-term impact of age and TBI on cognitive abilities.

Before transplantation, the average IQ scores of all patients in this study were in the normal range. One year after transplantation, average IQ scores of patients aged 5 and younger had declined sharply. But scores of most patients rebounded in subsequent years. Five years after the procedure, IQ scores for most patients, even the youngest survivors, had largely recovered and fell within the range of normal intelligence.

Patients in the high-risk group were the lone exception. IQ scores of patients who were both aged 3 or younger when their transplants occurred and who received TBI failed to recover from the first-year decline. Five years after transplantation, these survivors had average IQ scores in the low-normal range of intelligence. Their scores were more than 16 points lower than the scores of patients who were just as young when their transplants occurred but did not receive TBI.

Of the 72 patients in this study whose transplants included TBI, researchers found there was a long-term impact on intellectual functioning only of patients who were aged 3 or younger at transplantation.

"The significant first-year decline reflects the intensity of transplantation, which our results suggest leads to greater disruption in development in the youngest children than was previously recognized," said the study's first author Victoria Willard, Ph.D., a St. Jude psychology department research associate.

Read more:
Youngest bone marrow transplant patients at higher risk of cognitive decline

Major study: Professor Thomas Preiss from ANU JCSMR who has been involved in an international project researching stem cells. Photo: Graham Tidy

Scientists, including some from Canberra, have identified a new type of stem cell which is easier to grow and manipulate as part of a major study detailing the changes cells undergo as they reprogram into stem cells.

Experts from across the globe, including some from the Australian National University John Curtin School of Medical Research, have carried out the most detailed study of how specialised body cells can be reprogrammed to be like cells from the early embryo.

"The ultimate goal with this work is to develop therapies in regenerative medicine which is a therapeutic approach whereby you would ultimately replace cells or tissues or organs that are failing in a patient with replacement parts that are made in a laboratory from the patient's own cells or from genetically highly similar stem cells," Professor Thomas Preiss from ANU's JCSMR said.

Professor Preiss said it was hoped the research could help speed up the development of treatments for many illnesses and conditions.

Advertisement

"There's a range of diseases where tissues are damaged or cells or lost. It ranges from neurodegenerative disease to spinal cord injuries, stroke, diabetes, blood and kidney diseases and ultimately perhaps even heart disease," he said.

"I'm not saying our publication immediately enables any of these therapies but we're working on the molecular basis of understanding the process of making cells that would be useful for this kind of therapy."

Fifty experts in stem cell biology and genomics technologies have been involved in Project Grandiose which mapped the detailed molecular process involved in the generation of induced pluripotent stem (iPS) cells.

Since the 2012 Nobel Prize winning discovery that body cells can in principle be coaxed to become iPS cells, there has been a surge in research to better understand iPS cell reprogramming.

View original post here:
Researchers identify stem cells that can be reprogrammed

Latest Exercise & Fitness News

MONDAY, Dec. 8, 2014 (HealthDay News) -- Some professional football players are seeking unproven stem cell therapies to speed their recovery from injuries. But experts are concerned that they may be unaware of the potential risks, a new report shows.

Stem cell therapy has attracted the attention of elite athletes. A number of National Football League (NFL) players have highlighted their use of those therapies and their successful recoveries.

Twelve NFL players are known to have received unapproved stem cell treatments since 2009.

"The online data on NFL players and the clinics where they obtained treatment suggest that players may be unaware of the risks they are taking," report co-author Kirstin Matthews, a fellow in science and technology policy at Rice University's Baker Institute for Public Policy, said in a university news release.

"Players who are official spokespersons for these clinics could influence others to view the therapies as safe and effective despite the lack of scientific research to support these claims," she added.

Most of the players receive treatment in the United States, but several have gone to other countries for stem cell therapies that aren't available in the United States.

"With the rise of new and unproven stem cell treatments, the NFL faces a daunting task of trying to better understand and regulate the use of these therapies in order to protect the health of its players," Matthews said.

The NFL and other sports leagues may need to evaluate and possibly regulate stem cell therapies in order to ensure the safety of their players, the report authors suggested.

The paper appears in a special supplement to the journal Stem Cells and Development.

See original here:
Some NFL Players Use Unproven Stem Cell Therapies: Report

PUBLIC RELEASE DATE:

4-Dec-2014

Contact: John Wallace wallacej@vcu.edu 804-628-1550 Virginia Commonwealth University @vcunews

Is the human immune system similar to the weather, a seemingly random yet dynamical system that can be modeled based on past conditions to predict future states? Scientists at VCU Massey Cancer Center's award-winning Bone Marrow Transplant (BMT) Program believe it is, and they recently published several studies that support the possibility of using next-generation DNA sequencing and mathematical modeling to not only understand the variability observed in clinical outcomes of stem cell transplantation, but also to provide a theoretical framework to make transplantation a possibility for more patients who do not have a related donor.

Despite efforts to match patients with genetically similar donors, it is still nearly impossible to predict whether a stem cell transplant recipient will develop potentially fatal graft-versus-host disease (GVHD), a condition where the donor's immune system attacks the recipient's body. Two studies recently published by the online journal Frontiers in Immunology explored data obtained from the whole exome sequencing of nine donor-recipient pairs (DRPs) and found that it could be possible to predict which patients are at greatest risk for developing GVHD and, therefore, in the future tailor immune suppression therapies to possibly improve clinical outcomes. The data provides evidence that the way a patient's immune system rebuilds itself following stem cell transplantation is representative of a dynamical system, a system in which the current state determines what future state will follow.

"The immune system seems chaotic, but that is because there are so many variables involved," says Amir Toor, M.D., member of the Developmental Therapeutics research program at Massey and associate professor in the Division of Hematology, Oncology and Palliative Care at the VCU School of Medicine. "We have found evidence of an underlying order. Using next-generation DNA sequencing technology, it may be possible to account for many of the molecular variables that eventually determine how well a donor's immune system will graft to a patient."

Toor's first study revealed a large and previously unmeasured potential for developing GVHD for which the conventional approach used for matching DRPs does not account. The conventional approach for donor-recipient compatibility determination uses human leucocyte antigen (HLA) testing. HLA refers to the genes that encode for proteins on the surface of cells that are responsible for regulating the immune system. HLA testing seeks to match DRPs who have similar HLA makeup.

Specifically, Toor and his colleagues used whole exome sequencing to examine variation in minor histocompatibility antigens (mHA) of transplant DRPs. These mHA are protein fragments presented on the HLA molecules, which are the receptors on cells' surface to which these fragments of degraded proteins from within a cell bind in order to promote an immune response. Using advanced computer-based analysis, the researchers examined potential interactions between the mHA and HLA and discovered a high level of mHA variation in HLA-matched DRPs that could potentially contribute to GVHD. These findings may help explain why many HLA-matched recipients experience GVHD, but why some HLA-mismatched recipients experience none remains a mystery. This seeming paradox is explained in a companion paper, also published in the journal Frontiers in Immunology. In this manuscript, the team suggests that by inhibiting peptide generation through immunosuppressive therapies in the earliest weeks following stem cell transplantation, antigen presentation to donor T cells could be diminished, which reduces the risk of GVHD as the recipients reconstitute their T-cell repertoire.

Following stem cell transplantation, a patient begins the process of rebuilding their T-cell repertoire. T cells are a family of immune system cells that keep the body healthy by identifying and launching attacks against pathogens such as bacteria, viruses or cancer. T cells have small receptors that recognize antigens. As they encounter foreign antigens, they create thousands of clones that can later be called upon to guard against the specific pathogen that presented the antigen. Over the course of a person's life, they will develop millions of these clonal families, which make up their T-cell repertoire and protect them against the many threats that exist in the environment.

This critical period where the patient rebuilds their immune system was the focus of the researchers' efforts. In previous research, Toor and his colleagues discovered a fractal pattern in the DNA of recipients' T-cell repertoires. Fractals are self-similar patterns that repeat themselves at every scale. Based on their data, the researchers believe that the presentation of minor histocompatability antigens following transplantation helps shape the development of T-cell clonal families. Thus, inhibiting this antigen presentation through immunosuppressive therapies in patients who have high mHA variation can potentially reduce the risk of GVHD by influencing the development of their T-cell repertoire. This is backed by data from clinical studies that show immune suppression soon after transplantation improves outcomes in unrelated DRPs.

The rest is here:
Predicting the storm: Can computer models improve stem cell transplantation?

PUBLIC RELEASE DATE:

3-Dec-2014

Contact: Veronica McGuire vmcguir@mcmaster.ca 90-552-591-402-2169 McMaster University @mcmasteru

Hamilton, ON (Dec. 3, 2014) - Scientists at McMaster University have discovered that human stem cells made from adult donor cells "remember" where they came from and that's what they prefer to become again.

This means the type of cell obtained from an individual patient to make pluripotent stem cells, determines what can be best done with them. For example, to repair the lung of a patient with lung disease, it is best to start off with a lung cell to make the therapeutic stem cells to treat the disease, or a breast cell for the regeneration of tissue for breast cancer patients.

Pluripotency is the ability stem cells have to turn into any one of the 226 cell types that make up the human body.The work challenges the previously accepted thought that any pluripotent human stem cell could be used to similarly to generate the same amount of mature tissue cells.

This finding, published today in the prestigious science journal Nature Communications, will be used to further drug development at McMaster, and potentially improve transplants using human stem cell sources.

The study was led by Mick Bhatia, director of the McMaster Stem Cell and Cancer Research Institute. He holds the Canada Research Chair in Human Stem Cell Biology and he is a professor in the Department of Biochemistry and Biomedical Sciences of the Michael G. DeGroote School of Medicine.

"It's like the stem cell we make wants to become a doctor like its grandpa or an artist like its great-grandma," said Bhatia.

"We've shown that human induced pluripotent stem cells, called iPSCs, have a memory that is engraved at the molecular/genetic level of the cell type used to make them, which increases their ability to differentiate to the parent tissue type after being put in various stem cell states.

Continued here:
Not all induced pluripotent stem cells are made equal: McMaster researchers

MIAMI (PRWEB) December 01, 2014

GlobalStemCellsGroup.com has announced plans to team with Portal Medestetica, the largest physician portal in Lain America, to launch Portalstemcells.com, a new portal dedicated to providing physicians in Spain and Latin America with relevant information, clinical research news and products relating to stem cells and regenerative medicine.

The new collaboration between Global Stem Cells Group and Portal Medestetica will answer a growing need to expand the reach of high-impact news, studies and breakthroughs, and significantly advance the clinical utilization of stem cell research and clinical trials throughout Latin America. The Portalstemcells.com site is designed to help promote the latest state-of-the-art developments in regenerative medicine as they become available, and to share educational content with physicians throughout the region.

Portalstemcells.com will be the ideal vehicle to promote education and cutting-edge science throughout the region, says Ricardo de Cubas, founder of Global Stem Cells Group. The potential of regenerative medicine and stem cells therapies inspiring the medical community to find real opportunities to repair or replace tissue damaged from disease, relieve pain and provide the potential for curing chronic diseases where no cure existed before.

The Portalstemcells.com site is aimed at fostering growth and ethical development in the fast-moving field of stem cell medicine by filling a gap in the resources available throughout Latin America. The goal is to elevate the delivery of stem cell science in order to impact the lives of many patients worldwide.

For more information visit the Global Stem Cells website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

Read the rest here:
Global Stem Cells Group and Portal Medestetica to Launch Latin American Stem Cell Portal

New research has found evidence that stem cells could be used to correct genetic defects in skin and to treat certain rare diseases.

Three separate studies by scientists in the US, Europe and Japan have raised hopes that the methods could be used to develop treatments for a range of problems, including epidermolysis bullosa.

It is a disorder wheresufferers are born with extensive blistering and patches of missing skin.

They areleft with extremely fragile skin for all of their lives.

In the first study, the researchers used Induced Pluripotent Stem Cells (iPSCs) - adult cells that are reprogrammed to an embryonic stem cell-like state.

The scientists took diseased cells from three adult patients withepidermolysis bullosa.

The researchers converted the cells into iPSCs and used specialist tools to edit and fix the mutation in the genetic code responsible for defective collagen protein production, which causes the condition.

They then grew pieces of human skin that produced the correct collagen, and grafted them into mice where they lasted for three weeks.

It i's hoped the risk of rejection in humans will be minimal because the skin is made from the patient's own cells.

A second study confirmed these findings in the lab, showing that it is possible to genetically correct iPSCs from mice with epidermolysis bullosa and use the repaired cells to heal blistered skin.

Continued here:
Scientists use stem cells to correct skin defects

preservation laboratory, where stem cells were kept for use in transplants in children whose bone marrow has been damaged during chemotherapy.

Concerns were first raised when Sophie Ryan-Palmer, 12, who had acute lymphoblastic leukaemia, failed to make progress after her transplant in June 2013, which involved using a donors stem cells rather than her own.

She had been diagnosed with leukaemia at the age of two and had undergone three previous transplants. She began fundraising for cancer charities when she was six.

By October last year the hospital had identified that a higher than usual proportion of eight children who had undergone stem cell transplantation between March and August had suffered what doctors call delayed engraftment. But by the time it stopped freezing stem cells on site at its base in Bloomsbury, central London, and launched an investigation, three of the eight had died.

Ryan Loughran, aged 13 months, from Bournemouth, died on July 10. Sophie, from Sunbury in Middlesex, followed on July 17. Katie Joyce, from Hertfordshire, died on October 6. A fourth patient, Muhanna al-Hayany, aged five, died in August this year. He had come from Kuwait to have the treatment. Following the deaths it was discovered that the method used to freeze the stem cells had inexplicably stopped working and that, although still alive, the cells were unable to mature properly.

At the inquest, Katie Beattie, the barrister representing Katie Joyces family, questioned whether the girls transplant in August should have been suspended, knowing Sophie and Ryan had died the previous month. Great Ormond Street went ahead even though there was plenty of time to stop it, she said.

Doctors from the hospital told St Pancras coroners court that they regretted not halting transplants sooner and Katies life might have been saved if they had. But they said they believed they were doing the right thing by continuing with the transplants because cancer doesnt wait.

Great Ormond Street said it has since overhauled its procedures to prevent further incidents, but is still investigating why the freezing process stopped working.

A spokesman said: Before giving our patients any frozen cells we carried out tests, which are standard across most laboratories in the UK, to ensure they were alive and viable. All of the samples passed these tests, so there was nothing to suggest there was a problem at this stage.

The coroner, Mary Hassell, is expected to deliver verdicts on all four deaths on Tuesday.

Read more here:
Stem cell failure 'led to children's deaths' at Great Ormond Street

The Saint Mary's student club, SMC Stands up to Cancer, held a bone marrow registration drive Friday. Registrants' genetic information will be added to the Be the Match marrow database which searches for possible matches with blood cancer patients. Suitable donors can provide bone marrow or peripheral blood stem cells to patients, saving lives.

Allison Lukomski, a communicative sciences and disorders major, was a match for a female cancer patient from last years drive. She said it is very rewarding, knowing she was able to help someone else.

"You could save a life," Lukomski said, "and I just think it is so incredible and it is such an incredible experience I had, my family had, everyone in my family decided to join because they thought it was a really cool process." She said everyone asks about the pain, but once they realize how much information there is every step of the way, many people sign up.

This is the second year for the bone marrow drive. For more information on joining the bone marrow donation registry, visit Be The Match.

View post:
Saint Mary's holds bone marrow drive

PUBLIC RELEASE DATE:

20-Nov-2014

Contact: Jessica Mikulski jmikulski@nyee.edu 212-979-4274 The Mount Sinai Hospital / Mount Sinai School of Medicine @mountsinainyc

The National Eye Institute (NEI), a division of the National Institutes of Health, has awarded researchers at the Icahn School of Medicine at Mount Sinai a five-year grant totaling $1 million that will support an effort to re-create a patients' ocular stem cells and restore vision in those blinded by corneal disease.

About six million people worldwide have been blinded by burns, trauma, infection, genetic diseases, and chronic inflammation that result in corneal stem cell death and corneal scarring.

There are currently no treatments for related vision loss that are effective over the long term. Corneal stem cell transplantation is an option in the short term, but availability of donor corneas is limited, and patients must take medications that suppress their immune systems for the rest of their lives to prevent rejection of the transplanted tissue.

A newer proposed treatment option is the replacement of corneal stem cells to restore vision. The grant from the NEI will fund Mount Sinai research to re-create a patient's own stem cells and restore vision in those blinded by corneal disease. Technological advances in recent years have enabled researchers to take mature cells, in this case eyelid or oral skin cells, and coax them backward along the development pathways to become stem cells again. These eye-specific stem cells would then be redirected down pathways that become needed replacements for damaged cells in the cornea, in theory restoring vision.

"Our findings will allow the creation of transplantable eye tissue that can restore the ocular surface," said Albert Y. Wu, MD, PhD, Assistant Professor, Department of Ophthalmology at the Icahn School of Medicine at Mount Sinai and principle investigator for the grant-funded effort. "In the future, we will be able to re-create a patient's own corneal stem cells to restore vision after being blind," added Dr. Wu, also Director of the Ophthalmic Plastic and Reconstructive Surgery, Stem Cell and Regenerative Medicine Laboratory in the Department of Ophthalmology and a member of the Black Family Stem Cell Institute at Icahn School of Medicine. "Since the stem cells are their own, patient's will not require immunosuppressive drugs, which would greatly improve their quality of life."

Specifically, the grant will support efforts to discover new stem cell therapies for ocular surface disease and make regenerative medicine a reality for people who have lost their vision. The research team will investigate the most viable stem cell sources, seek to create ocular stem cells from eyelid or oral skin cells, explore the molecular pathways involved in ocular and orbital development, and develop cutting-edge biomaterials to engraft a patient's own stem cells and restore vision.

###

See the article here:
Mount Sinai researchers awarded grant to find new stem cell therapies for vision recovery

Congestive Heart Failure Treatment Using Stem Cells

Congestive Heart Failureor CHF is a state wherein the heart does not have the capability to properly function as a pump. As a result of the cardiac-malfunction the oxygen pumped into the body is insufficient. Congestive heart failure is generally caused bysimultaneousillnesses. Illnesses that weaken the heart muscle,or diseases that trigger the heart muscles to become stiff, or illnesses that create an increase in oxygen demands for the body which consequently increases the supply for fresh oxygen by the body when the heart is incapable of producing oxygen-rich blood at the level needed.

Congestive heart failure and ishchemic heart disease can have an impact on numerous organs in the body. For instance, the injured areas of the heart directly affected by the sickness does not have the capability to produce enough blood for the kidneys, which then affect their capability to excrete water and salt (sodium). The distressed kidney function may cause the body to retain more fluids than needed by the body. The lungs also may develop pulmonary edema (PE).

PE occurs when the fluid in the lungs diminishes a persons ability to exercise normally. Fluid might likewise accumulate inside the liver, which directly affects it function by impairing the livers capability to create important proteins and also in helping clear the body of harmful elements and/ortoxins. The intestines might also turn out to be much less effective in being able to absorb the vitamins, nutrients and medicines a human needs. The fluids in the body can also accumulate quickly which could result to edema (severe swelling) of the ankles and feet.

An Ejection fraction of 20% would be considered a dangerous level and therefore indicates a highly advanced stage of heart failure. Healthy people usually have ejection fractions in between 52% and 68%.

View post:
Stem Cell Treatment Congestive Heart Failure | CHF Stem ...

Woodland Hills, CA (PRWEB) November 19, 2014

Longtime skincare industry professional Nancy Ryan announces the launch of NR Skin, featuring a line of efficacious products that deliver various skin rejuvenation and age repair benefits for all skin types.

According to Dr. Lisa Benest, Board-certified dermatologist, Burbank, CA, the NR Skin line offers a range of daily skincare and skin rejuvenation products distinguished by high concentrations of powerhouse ingredients that are known for their anti-aging properties, such as antioxidant vitamins and minerals, plant stem cells, lipids, as well as peptides. Dr. Benest notes that NR Skin products offer pure, clean ingredients that feel great on the skin and deliver visible results.

Backed by more than 20 years of skincare industry experience and expertise, NR Skin Founder and CEO Nancy Ryan comments, the creation of NR Skin is a culmination of my lifes work and lifelong passion for excellence in skincare. Im thrilled to help people improve their quality of life by achieving healthy, beautiful skin through such pure and effective products.

Before establishing NR Skin in 2014, Ms. Ryan led Pro-Med Consulting, Inc. for 21 years, which was built upon the core mission of giving dermatologists, plastic surgeons and medical spas a viable way to build their own brand equity and expand their businesses with private label, medical-grade skin care products. Over the years, she developed numerous relationships with leading physicians, whose businesses grew significantly by offering patients her high-performance products that bore each doctors name.

Prior to this successful venture, she worked for two pioneering skin care companies, Ortho Dermatologics, (makers of Retin-A Micro/Renova) and NeoStrata, where she had the opportunity to learn about skin care chemistry and the most effective ways to treat various skin conditions with specific product ingredients.

The NR Skin product line consists of: the following clinically tested products: Age-defying Peptide Cream; Citrus Stem Cell Fusion Cream, Neuro-Peptide Serum. Retinol Complex Treatment Super Antioxidant Cream, Super C Serum Treatment, Comfort Cleanser, Lash Teez Eyelash Growth Serum and Sunscreen Lotion SPF30.

To view products and recommended regimens, visit: http://www.nrskin.com Follow us on Facebook: http://www.facebook.com/nrskin and on Twitter: @nrskincompany

Read more from the original source:
NR Skin Launches Anti-Aging Product Line

Kilian Before After Stemlogix Stem Cell Therapy
dog with arthritis treated with autologous stem cells.

By: mark Greenberg

More:
Kilian Before & After Stemlogix Stem Cell Therapy - Video

NEW YORK (TheStreet) -- Shares ofNeoStem (NBS) plummeted 25.52% to $5.05 in late morning trading Tuesdayafter the biotech company announced poor results from a trial of its proprietary cardiac stem-cell therapy NBS10.

NBS10, which used to be called AMR-001, missed two primary endpoints in the study to test the therapy's efficacy.The stem-cell therapy comesfrom a patient's own bone marrow and is injected into patients after a heart attack. The stem cells are then supposed to help blood flow and build cardiac muscle.

NeoStem's trial used non-invasive imaging to monitor blood flow through the heart six months after a one dose of NBS10 or a placebo. The study showed no difference between NBS and placebo, NeoStem said.

Must Read:NeoStem's Stem Cell Therapy Fails Mid-Stage Heart Attack Study

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Jim Cramer's protg, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Read the original:
NeoStem (NBS) Stock Plummets Today on Disappointing Cardiac Stem-Cell Therapy Data

Blue Horizon's Special Skin Serum Stem Product Fact Sheet

Our Stem Cell Skin Care is a potent anti-aging innovation derived from non-embryonic human stem cell research. Blue Horizon International has infused medicines most promising clinical advances into this powerful skin care product.

Cytokine action, epidermal growth factors (EGFs), short and long-chained hyaluronic acid and ceramides combat the effects of aging and deliver unique skin benefits without surgery.

Our formulation is safe, having passed toxicology tests in accordance with European Union regulation 1223/2009/EC.

Patents are pending.

Our skin care is derived from what stem cell scientists call a conditioned medium. Here, human stem cells from placentas and umbilical cords condition the culture medium by releasing cytokines and other skin regenerating proteins that become available for skin repair. We stabilize the liberated cytokines, rendering them safe and accessible for aesthetic skin improvement. The conditioned medium is the base for our stem cell skin care products.

An independent skin test on twenty individuals aged 46 to 81 found a 23% reduction in skin roughness, including a decrease in the appearance of fine lines, wrinkles and scars.

Cytokines are one of todays most exciting captured biological processes, because they govern so many regenerative functions. The cytokine group of chemical regulators includes a diverse assortment of interleukins, interferons and growth factors that control anti-aging and activate the bodys immune system.

Cytokines stimulate, propagate and regulate new cell production in human skin. These messaging molecules mobilize cell division to help heal age related damage. Cytokines have powerful influence over skin texture and quality because they regulate cell shape, metabolism and migration from one location to another.

Several stem cell skin care ranges claim cytokine-style benefits. However, human stem cell cytokines are more biologically compatible with human skin than cytokine proteins from other sources.

Continued here:
Stem Cell Skin Care - BlueHorizonSkinCare.com

Pioneers of transplantation John Gurdon
Interview with Sir John Gurdon, developmental biologist and forefather of stem cell medicine. The footage, produced by Figment Productions, formed part of an exhibition organised by the MRC...

By: Medical Research Council

Follow this link:
Pioneers of transplantation John Gurdon - Video

Stem Cell Therapy BACKSTAGE

By:

Link:
Stem Cell Therapy BACKSTAGE - Video

Chicago, Illinois (PRWEB) October 30, 2014

On October 26th at the Mid American Regenerative and Cellular Medicine Showcase in Chicago, leading applied stem cell research scientist Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna presented talks on New Techniques for Enhancing Stem Cell Therapy Effectiveness and Orthopedic Surgical Applications For Stem Cells.

Dr. Riordan focused on historical medical uses of amniotic membrane and the properties of AlphaGEMS that include: wound healing; inflammation and pain reduction; fibrosis risk reduction; growth factor source; adhesion reduction; regeneration support and stem cell enhancement, specifically regarding the mesenchymal stem cells contained within BMAC.

Dr. McKenna discussed the latest applications of BMAC stem cells in orthopedic surgeries like anterior cruciate ligament (ACL) reconstruction and how BMAC injections can virtually eliminate infection risk, reduce complications, increase graft strength, reduce post-surgical inflammation and significantly reduce recovery time. Dr. McKenna also talked about how bone marrow can now be safely and relatively painlessly harvested using his patented BioMAC catheter under local, not general anesthesia.

Dr. Riordan and Dr. McKenna are co-founders of the Riordan-McKenna Institute (RMI), which will be opening soon in Southlake, Texas. RMI will specialize in regenerative orthopedics including non-surgical stem cell therapy and stem cell-enhanced surgery using bone marrow aspirate concentrate (BMAC) and AlphaGEMS amniotic tissue product.

Other noteworthy speakers in attendance included: Paolo Macchiarini, MD-PhD, Arnold Caplan, PhD and Mark Holterman, MD-PhD. Dr. Macchiarini and Dr. Holterman are well known for their work on the first stem cell trachea transplant. Dr. Caplan discovered the mesenchymal stem cell and is commonly referred to as the father of the mesenchymal stem cell.

About Neil Riordan PhD

Dr. Riordan is the co-founder of the Riordan-McKenna Institute (RMI), which will be opening soon in Southlake, Texas. RMI will specialize in regenerative orthopedics including non-surgical stem cell therapy and stem cell-enhanced surgery using bone marrow aspirate concentrate (BMAC) and AlphaGEMS amniotic tissue product.

Dr. Riordan is founder and chief scientific officer of Amniotic Therapies Inc. (ATI). ATI specializes in amniotic tissue research and development. Its current product line includes AlphaGEMS and AlphaPATCH amniotic tissue-based products.

Dr. Riordan is the founder and chairman of Medistem Panama, Inc., (MPI) a leading stem cell laboratory and research facility located in the Technology Park at the prestigious City of Knowledge in Panama City, Panama. Founded in 2007, MPI stands at the forefront of applied research on adult stem cells for several chronic diseases. MPI's stem cell laboratory is ISO 9001 certified and fully licensed by the Panamanian Ministry of Health. Dr. Riordan is the founder of Stem Cell Institute (SCI) in Panama City, Panama (est. 2007).

More here:
Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid ...

OTTAWA - A coalition of Canadian stem cell advocates, researchers and charities is calling for $1.5 billion in private and public funding for stem cell therapy over the next 10 years.

The coalition's action plan is aimed at cementing Canada's reputation as a stem cell leader, one that uses stem cell science to reduce suffering and death from cardiovascular diseases, cancer, diabetes, vision loss, spinal cord injuries and other conditions.

James Price, the president and CEO of the Canadian Stem Cell Foundation, says the action plan could help millions of people with new, life-changing therapies.

The action plan's call for funding includes a $50 million scaled annual average commitment by the federal government.

The Centre for Commercialization of Regenerative Medicine estimates the action plan could also create more than 12,000 jobs due to the growth of existing companies and the development of new enterprises aimed at global markets.

More:
Medical groups call for major stem cell investment from public, private sector

Published: Tuesday, October 28, 2014 at 12:39 p.m. Last Modified: Tuesday, October 28, 2014 at 12:39 p.m.

Jaimonee Hagins, 12, a seventh-grade student at Howard Middle School, needs a blood and marrow transplant to help battle the disease, which often has her in such deep pain she cannot attend classes.

Understanding only too well the ravages of sickle cell anemia is her mother, Charlet Harrison, of Ocala. She and her brother Myron Harrison grew up with the condition.

Sickle cell anemia is the most common form of sickle cell disease, an inherited disorder in which red blood cells are abnormally shaped. This results in painful episodes, serious infections, chronic anemia and damage to body organs.

According to the National Institutes of Health, a blood and marrow stem cell transplant can work well for treating sickle cell anemia as it replaces faulty stem cells with healthy ones. Stem cells are found in bone marrow.

According to Dr. Ali Nassar of Munroe Heart, A bone marrow transplant produces new cells. Donor to recipient genetically must be a close match. Only with identical twins is the match 100 percent. If the procedure is a success, it is considered a cure.

I hope I will find a donor. If they help me, they will save my life, Jaimonee said.

When asked what has been the most difficult part of her disorder, she said the surgeries. She also said the frequent pain is real achy.

According to her mother, Jaimonees surgeries have included removal of her spleen, at age 1, and her gall bladder, at age 4. She has had episodes affecting other major organs.

Blood cells get clogged. Normally, they are round in shape in order to flow through the body. When they get clogged, they cause pain, Charlet Harrison said. A clog on an arm or leg is easy to get over; it is when they get clogged in your heart or another major organ that damage occurs. The spleen and gall bladder, with sickle cell patients, are the first to go. Seventy-five percent of patients have these organs removed.

See more here:
Blood, donor drive to benefit girl with sickle cell anemia